General
Preferred name
ORANTINIB
Synonyms
SU6668 ()
TSU-68 ()
(Z)-SU6668 ()
(Z)-TSU-68 ()
SU 6668 ()
TSU-68, SU-6668 ()
NSC 702827 ()
TSU-68 (SU6668) ()
Rosiglitazone + metformin ()
(Z)-Orantinib ()
NSC-702827 ()
SU-6668 ()
Orantinib (SU6668) ()
P&D ID
PD011179
CAS
252916-29-3
210644-62-5
Tags
available
probe
drug candidate
Drug indication
Diabetic complication
Advanced solid tumour
Drug Status
investigational
Max Phase
3.0
Probe info
Probe selectivity
protein-selective
Probe type
calculated probe
Probe sources
Probe targets
[[ compound.targets[t].gene_name ]]
Probe control
Probe control not defined
Orthogonal probes
81
No orthogonal probes found
Similar probes
1
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Orantinib is a multi-kinase inhibitor.
(GtoPdb)
DESCRIPTION
Potent AMPK activator
(Tocris Bioactive Compound Library)
DESCRIPTION
PDGFR, VEGFR and FGFR inhibitor
(Tocriscreen Plus)
DESCRIPTION
PDGFR, VEGFR and FGFR inhibitor
(Tocriscreen Total)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
0
Compound Sets
24
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Drugs
Clinical kinase drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugMAP
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
JUMP-Target 1 Compound Set
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
Other bioactive compounds
PKIDB
Probe Miner (suitable probes)
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
Tocriscreen Plus
Tocriscreen Total
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
32
Molecular Weight
310.13
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
3
Rotatable Bonds
4
Ring Count
3
Aromatic Ring Count
2
cLogP
3.14
TPSA
82.19
Fraction CSP3
0.22
Chiral centers
0.0
Largest ring
6.0
QED
0.76
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Targets
PDGFRA,PDGFRB
Target Type
Enzyme-Linked Receptors
Pathway
Angiogenesis
Tyrosine Kinase/Adaptors
Chromatin/Epigenetic
Apoptosis
Protein Tyrosine Kinase/RTK
Target
FGFR1
PDGFR??
Flk1
PDGFR¦Â
AURKA, AURKB, EGFR, FGFR1, FGFR2, KDR, PDGFRA, PDGFRB
RTK inhibitor
AURKB
FGFR
VEGFR
KDR
PDGFRB
Primary Target
PDGFR
MOA
PDGFR inhibitor
Inhibitor
FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor
Source data
